Share this page

For customers outside of Japan

Sponsor’s Voice

“EPS was professional, conscientious and responsive throughout a phase 3 study in pediatric patients with arare disease that greatly contributed to its success. Together, OPKO and EPS achieved key milestones with timely patient enrollment and a successful PMDA approval. We hope to partner again in the future.”

  High Level of Professionalism

EPS Ever Progressing Japanese, Chinese & Asian CRO!

"Ever Progressing System" is the spirit of EPS, and is the origin of the company name. It is expected that the people who work here will grow through our service to clients, and improve the quality of life (QOL) of all our stakeholders.

We are a CRO that is always conscious of these words and continues to progress. We will continue to challenge ourselves to meet the ever-changing needs of our customers and will never stop until we do so!

More Detail

We provide a One Stop Solution for all your outsourcing needs!

Our "One Stop Solution" brings together the individual services needed by you, our customers. Seamless communication helps you understand the status of each service and leads your project to the optimal quality completion goal.

More Detail

Your Gateway for Clinical Research in Japan, China, and Asia

EPS Corporation an EPS Group Company, serves as a clinical research "Gateway" to Japan, China, and Asia.

As your "Gateway", we provide you with clinical research and market access to Japan, China, and Asia.

More Detail


October 18, 2023

Notice of Executive Structure

Read More


Sep 20, 2023

EPS Corporation was selected as a finalist in the "Best CRO/CDMO" category of the "Citeline Pharma Intelligence Awards Japan 2023".

Sep 6, 2023

EPS will be exhibiting at the Outsourcing In Clinical Trials Southern California 2023 in San Diego, CA

  • Want to enter the
    Asian healthcare market?
    Let us open the door for you.
  • Japan

    A rapidly aging society.
    A growing demand for healthcare.
    We help you navigate the documentary and
    regulatory complexities of Japan.

    $4175 126

  • Taiwan

    A doorstep to the vast Chinese market.
    We solidified our presence here in 2011
    through a strategic acquisition.

    $1632 24

  • South Korea

    Emerging as a top leader of clinical trials in Asia.
    A CRO providing support for clinical trials and
    application approval since 2007.

    $2150 52

  • Australia

    A very friendly tax and regulatory environment.
    We’ve had outstanding success with
    clinical trials here since 2006.

    $5563 25

  • China

    A country with a phenomenal growth rate.
    Our expert multilingual staff has over
    10 years experience here.

    $436 1398

  • Philippines

    Tap into a huge ASEAN country.
    Since 2004 we have been leveraging
    this deep clinical resource pool.

    $124 108

  • Hong Kong

    Offers efficient entry into the massive
    Chinese market. With a base in Hong Kong
    since 2008, we are situated to benefit
    from evolving legislation.

    $2221 80/85

  • India

    Home to 16% of the world's population,
    20% of its disease. A growing biotech
    market presents tremendous opportunity
    for clinical trials.

    $65 1366

  • Malaysia

    Multi-ethnic population and competitive
    costs. Malaysia has an established healthcare
    infrastructure that provides a solid foundation
    for clinical research.

    $407 32

  • Singapore

    A robust pharmaceutical and biotech center
    for Asia. The country's high standards have
    made Singapore an ideal headquarters for
    EPSI's global arm since 2000.

    $2580 60

We will tailor an ideal solution for your specific needs.

Contact Us